Fig. 1From: A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorderStandard Protocol Items Recommendations for Interventional Trials (SPIRIT) figureBack to article page